Nathan J. Alves, PhD, is an Assistant Professor in the Department of Emergency Medicine at the Indiana University School of Medicine. Dr. Alves joined the EM Department as the first non-MD tenure-track faculty member (~100 clinical faculty members) directly following completion of a National Academy of Science Fellowship at the Naval Research Laboratory in Washington, DC. As a Chemical and Biomolecular Engineer with a primarily faculty appointment in a clinical department, Dr. Alves is uniquely situated to access relevant patient samples to develop novel methods of treating and diagnosing disease. The research he conducts is centered on the development of translational technologies, treatments and techniques that can be utilized to have a positive impact on people’s lives and has resulted in over 25 peer-reviewed scientific publications and 8 patent pending technologies. His lab is highly interdisciplinary integrating synthetic biology through recombinant protein expression, synthetic chemistry through molecule design and chemical synthesis, analytical chemistry through various purification and characterization techniques, and direct implementation of diverse nanoparticle formulations in both in vitro and in vivo disease models. Dr. Alves is also the Co-Founder and President of Indiana Lysis Technologies LLC, a nanoparticle based therapeutics company whose goal is to develop and commercialize safer clot lysis technologies to treat life threatening venous thrombosis, including Pulmonary Embolism (PE).